JP7562417B2 - キメラノッチ受容体 - Google Patents

キメラノッチ受容体 Download PDF

Info

Publication number
JP7562417B2
JP7562417B2 JP2020555518A JP2020555518A JP7562417B2 JP 7562417 B2 JP7562417 B2 JP 7562417B2 JP 2020555518 A JP2020555518 A JP 2020555518A JP 2020555518 A JP2020555518 A JP 2020555518A JP 7562417 B2 JP7562417 B2 JP 7562417B2
Authority
JP
Japan
Prior art keywords
cell
cells
receptor
nucleic acid
notch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520813A5 (https=
JP2021520813A (ja
JPWO2019199165A5 (https=
Inventor
アムセン、デルク
Original Assignee
スティヒティング・サンクイン・ブルートフォールズィーニング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スティヒティング・サンクイン・ブルートフォールズィーニング filed Critical スティヒティング・サンクイン・ブルートフォールズィーニング
Publication of JP2021520813A publication Critical patent/JP2021520813A/ja
Publication of JP2021520813A5 publication Critical patent/JP2021520813A5/ja
Publication of JPWO2019199165A5 publication Critical patent/JPWO2019199165A5/ja
Application granted granted Critical
Publication of JP7562417B2 publication Critical patent/JP7562417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2020555518A 2018-04-10 2019-04-10 キメラノッチ受容体 Active JP7562417B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18166498.8 2018-04-10
EP18166498 2018-04-10
PCT/NL2019/050212 WO2019199165A1 (en) 2018-04-10 2019-04-10 Chimeric notch receptors

Publications (4)

Publication Number Publication Date
JP2021520813A JP2021520813A (ja) 2021-08-26
JP2021520813A5 JP2021520813A5 (https=) 2022-04-19
JPWO2019199165A5 JPWO2019199165A5 (https=) 2022-04-19
JP7562417B2 true JP7562417B2 (ja) 2024-10-07

Family

ID=62063276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555518A Active JP7562417B2 (ja) 2018-04-10 2019-04-10 キメラノッチ受容体

Country Status (9)

Country Link
US (1) US20210139556A1 (https=)
EP (1) EP3774867A1 (https=)
JP (1) JP7562417B2 (https=)
KR (1) KR20210008840A (https=)
CN (1) CN112243442A (https=)
AU (1) AU2019252878B2 (https=)
CA (1) CA3096812A1 (https=)
IL (1) IL277859A (https=)
WO (1) WO2019199165A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116790647B (zh) * 2023-02-06 2024-04-16 森瑞斯生物科技(深圳)有限公司 一种低背景、高信号强度的2-吡咯烷酮生物传感器及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516486A (ja) 2014-06-04 2017-06-22 フレッド ハッチンソン キャンサー リサーチ センター Ｎｏｔｃｈ １および／またはＮｏｔｃｈ ２アゴニストを用いた幹細胞の増殖および生着
WO2017123559A2 (en) 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
JP2017531448A (ja) 2014-10-06 2017-10-26 アシスタンス パブリック−ホピトー デ パリ Ｔ細胞前駆細胞を生成するための方法
WO2018039247A1 (en) 2016-08-23 2018-03-01 The Regents Of The University Of California Proteolytically cleavable chimeric polypeptides and methods of use thereof
JP2018506293A (ja) 2015-02-24 2018-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結合誘発型転写スイッチ及びその使用方法
WO2018236825A1 (en) 2017-06-19 2018-12-27 Cell Design Labs, Inc. METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047878A1 (en) * 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
CN104402998A (zh) * 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
SG191039A1 (en) * 2010-12-15 2013-08-30 Wyeth Llc Anti-notch1 antibodies
EP2970479B1 (en) * 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516486A (ja) 2014-06-04 2017-06-22 フレッド ハッチンソン キャンサー リサーチ センター Ｎｏｔｃｈ １および／またはＮｏｔｃｈ ２アゴニストを用いた幹細胞の増殖および生着
JP2017531448A (ja) 2014-10-06 2017-10-26 アシスタンス パブリック−ホピトー デ パリ Ｔ細胞前駆細胞を生成するための方法
JP2018506293A (ja) 2015-02-24 2018-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結合誘発型転写スイッチ及びその使用方法
WO2017123559A2 (en) 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
WO2018039247A1 (en) 2016-08-23 2018-03-01 The Regents Of The University Of California Proteolytically cleavable chimeric polypeptides and methods of use thereof
WO2018236825A1 (en) 2017-06-19 2018-12-27 Cell Design Labs, Inc. METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Klebanoff CA. et al.，Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells，Cell，2016年，167(2)，304-306
Kondo T. et al.，Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy，Nature communications，2017年，8:15338，p.1-13
Mathieu M. et al.，Notch signaling regulates PD-1 expression during CD8(+) T-cell activation，Immunology and cell biology，2013年，91(1)，82-88
Pan T. et al.，Notch Signaling Pathway Was Involved in Regulating Programmed Cell Death 1 Expression during Sepsis-Induced Immunosuppression，Mediators of inflammation，2015年，Vol.2015, ID:539841，p.1-9
Roybal KT. et al.，Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors，Cell，2016年，167(2)，419-432, e1-e6
Roybal KT. et al.，Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits，Cell，2016年，164(4)，770-779

Also Published As

Publication number Publication date
AU2019252878B2 (en) 2024-02-22
KR20210008840A (ko) 2021-01-25
IL277859A (en) 2020-11-30
US20210139556A1 (en) 2021-05-13
CN112243442A (zh) 2021-01-19
WO2019199165A1 (en) 2019-10-17
AU2019252878A1 (en) 2020-11-26
EP3774867A1 (en) 2021-02-17
CA3096812A1 (en) 2019-10-17
JP2021520813A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
US12565535B2 (en) Chimeric antigen receptors targeted to PSCA
JP7217970B2 (ja) 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
JP2023109968A (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP2023011003A (ja) ウイルスおよびその他の感染を処置するための免疫細胞組成物および使用の方法
JP7372728B2 (ja) 改変ｔ細胞に関する方法および組成物
US10647997B2 (en) Modified effector cell (or chimeric receptor) for treating disialoganglioside GD2-expressing neoplasia
CN104379599B (zh) 能用于过继性细胞疗法的多肽
JP7233720B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
CN110248669A (zh) 工程化天然杀伤细胞及其用途
KR102790597B1 (ko) 메모리 기능을 갖는 t세포 또는 b세포의 증강제, 악성 종양 재발 억제제 및 t세포 또는 b세포에 메모리 기능을 유도하는 유도제
KR20190098747A (ko) 입양 세포 치료법을 위한 조작된 세포의 제조방법
JP2023153870A (ja) 改変ｃａｒ－ｔ
BR112020007710A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
CN107810267A (zh) 修饰的γδ细胞及其用途
JP2021508456A (ja) Ｃａｒ ｔ細胞の作製を改良するための方法
CN112969470A (zh) 用于扩增抗原特异性car-t细胞、组合物的方法及其相关用途
CN115916963A (zh) 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
JP7562417B2 (ja) キメラノッチ受容体
US20230405047A1 (en) Methods and compositions for eliminating engineered immune cells
RU2777284C2 (ru) Сконструированные клетки - естественные киллеры и их применение
HK40052654A (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
HK40026612A (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240925

R150 Certificate of patent or registration of utility model

Ref document number: 7562417

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150